A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection

BioWest Therapeutics Inc60 enrolled

Overview

The objective of the study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for 12 weeks in patients with chronic hepatitis C genotype 1 infection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hepatitis C, Chronic

Interventions

CelgosivirDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18-65 years of age, inclusive * primary diagnosis of chronic HCV infection * non-responders to previous pegylated interferon-based therapy Exclusion Criteria: * patients naive to interferon-based therapy for chronic HCV infection

Locations (6)

Unnamed facility

Calgary, Alberta, Canada

Unnamed facility

Edmonton, Alberta, Canada

Unnamed facility

Vancouver, British Columbia, Canada

Unnamed facility

Winnipeg, Manitoba, Canada

Unnamed facility

Outcomes

Primary Outcomes

Safety analysis

HCV viral load

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.